Akari Therapeutics plc ADR (0.01 USD) (AKTX) is a publicly traded Healthcare sector company. As of May 21, 2026, AKTX trades at $3.51 with a market cap of $4.01M and a P/E ratio of 0.00. AKTX moved +0.53% today. Year to date, AKTX is -70.85%; over the trailing twelve months it is -93.40%. Its 52-week range spans $3.02 to $148.00. Analyst consensus is buy with an average price target of $27.00. Rallies surfaces AKTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Akari’s AKTX-101 ADC Wins ASCO Acceptance for KRAS-mutant Cancer Synergy: Akari Therapeutics secured its first ASCO abstract acceptance for AKTX-101’s RNA-splicing modulator ADC showing combination synergy with a KRAS inhibitor in KRAS-mutant pancreatic cancers. The full abstract will be published online May 21, 2026, ahead of planned Phase 1 initiation in late 2026/early 2027.
| Metric | Value |
|---|---|
| Price | $3.51 |
| Market Cap | $4.01M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $148.00 |
| 52-Week Low | $3.02 |
| Volume | 3.10K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-17.30M |
| Gross Margin | 0.00% |
2 analysts cover AKTX: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $27.00.